论文部分内容阅读
1 心血管系统药物欧共体批准勃林格英汉姆 /基因技术公司的单剂量抗血栓形成药 Metalyse(通用名 :tenec- teplase)上市 本品用于急性心肌梗死的治疗。今后 ,本品将陆续在德国、荷兰、瑞典、奥地利、丹麦和芬兰投放市场 ,并将在今、明两年继续投放其它国家的市场。该药是第一
1 Cardiovascular Drugs The European Community has approved the single-dose anti-thrombotic drug Metalyse (common name: tenec- teplase) of Boehringer Ingelheim / Genentech for marketing this product for the treatment of acute myocardial infarction. In the future, this product will be put on the market one after another in Germany, the Netherlands, Sweden, Austria, Denmark and Finland, and will continue to be put on the markets of other countries in the next two years. This medicine is the first